University of Miami Health System, Miller School of Medicine

New Cell Therapy Trial Launches for Patients with Severe COVID-19

FDA grants immediate authorization for clinical trial to test umbilical cord-derived mesenchymal stem cells in COVID-19 patients.

Newswise — An international team of scientists led by Camillo Ricordi, M.D., director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine, has been granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe cases of COVID-19.

“There is no time to waste,” said Dr. Ricordi, the principal investigator, who is the Stacy Joy Goodman Professor of Surgery. “Patients who die from COVID-19 have a median time of just 10 days between first symptoms and death. In severe cases oxygen levels in the bloodstream drop, and the inability to breathe pushes patients toward their end very quickly; any intervention that might prevent that trajectory would be highly desirable.”

The trial will be based at the University of Miami Health System and Jackson Health System. It is the result of a collaborative academic initiative sponsored by The Cure Alliance, a non-profit group of scientists and innovators dedicated to sharing knowledge and accelerating cures for all diseases. In response to the COVID-19 pandemic, The Cure Alliance has pivoted all resources to fighting the virus. The clinical protocol has been shared with other academic institutions throughout the world who want to test similar treatment strategies in the fastest and most efficient way possible.

“We are very grateful to the FDA’s Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, for performing four rounds of reviews in a record time — one week,” said Dr. Ricordi.

The FDA had previously authorized the testing of umbilical cord-derived mesenchymal stem cell products in patients with type 1 diabetes and Alzheimer’s disease at the University of Miami as part of other clinical trials. For the COVID-19 trial, Dr. Ricordi enlisted additional experts from around the world with extensive experience in infectious diseases, pulmonary medicine and critical care, while others provided expertise in cell-based product development and their use in clinical trials. The cell therapy is administered intravenously.




Filters close

Showing results

110 of 2916
Released: 14-Aug-2020 10:05 AM EDT
Why does COVID-19 impair your sense of smell?
University of Alabama at Birmingham

Hyposmia or anosmia, a decreased or complete loss of smell, has been widely reported in patients with COVID-19, often as a symptom noticed early on prior to other symptoms or even as the only symptom present in an otherwise asymptomatic patient.There are still many unknowns regarding COVID-19, but one common occurrence among those infected is smell loss.

Newswise: Researchers pivot from studying cancer and cystic fibrosis to launch trial of drug to fight COVID-19
14-Aug-2020 9:00 AM EDT
Researchers pivot from studying cancer and cystic fibrosis to launch trial of drug to fight COVID-19
University of Kansas Cancer Center

The University of Kansas Medical Center announced today a trial exploring a drug intended to fight the cytokine storm common in COVID-19.

Released: 14-Aug-2020 8:45 AM EDT
Many medical “rainy day” accounts aren’t getting opened or filled, study finds
Michigan Medicine - University of Michigan

One-third of the people who could benefit from a special type of savings account to cushion the blow of their health plan deductible aren’t doing so, according to a new study. And even among people who do open a health savings account (HSA), half haven’t put any money into it in the past year.

access_time Embargo lifts in 2 days
Embargo will expire: 18-Aug-2020 11:00 AM EDT Released to reporters: 14-Aug-2020 8:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 18-Aug-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Obesity a Major Risk for Severe COVID-19 Cases
Released: 13-Aug-2020 4:55 PM EDT
Obesity a Major Risk for Severe COVID-19 Cases
Hackensack Meridian Health

While the U.S. Centers for Disease Control and Prevention (CDC) advises that people of any age can contract COVID-19, obesity has emerged among the major risk factors for severe cases. With more than 40 percent of Americans classified as obese, experts caution that this is a growing concern.

Newswise: Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
Released: 13-Aug-2020 4:10 PM EDT
Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
American Academy of Ophthalmology (AAO)

The American Academy of Ophthalmology shares back-to-online school checklist to protect kids’ eyes from too much screen time.

Newswise: 240042_web.jpg
Released: 13-Aug-2020 3:05 PM EDT
A quick, cost-effective method to track the spread of COVID-19
Hokkaido University

A group of researchers have demonstrated that, from seven methods commonly used to test for viruses in untreated wastewater, an adsorption-extraction technique can most efficiently detect SARS-CoV-2. This gives us another tool to detect the presence and spread of the COVID-19 pandemic.

Released: 13-Aug-2020 2:40 PM EDT
Technion’s Nanofiber PPE Sticker Now In Mass Production
American Technion Society

The COVID-busting ‘Maya’ sticker developed by Technion researchers has gone into mass production. Comprised of a nanofiber sheet, the unique sticker can be easily adhered to a protective mask, significantly improving its effectiveness against the novel coronavirus.

13-Aug-2020 11:00 AM EDT
Massive, rapid vaccine production will require firms to share information
University of Michigan

As the world rushes to identify safe and effective vaccines and therapeutics to counter the COVID-19 epidemic, attention is turning to the next step: manufacturing these products at enormous scale.


Showing results

110 of 2916

close
1.22029